Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD7503 in Suspected NASH
NCT05864391Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of AZD7503 in Nonalcoholic steatohepatitis (NASH) (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events (AEs) up to 19 weeks and Number of subjects with serious adverse events (SAEs) up to 18 weeks. Started Mar 2023; status: terminated.
02
Drugs
AZD7503
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05864391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864391.